An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States.
VERDICT
The label
Markdown
read at $10.94
Phathom Pharmaceuticals, Inc. holds its Markdown at $10.94.
PHPhase · the trend structure carries the Markdown label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · passes the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-07-19
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 224 days
Price
$10.94
Valuation
N/A trailing · 7.60 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.49
SCREEN
The values screen, explained · five checks, plain English
Full pass across all five screens. This security clears the Titan Ethical Standard — its business and its balance sheet both stay inside the lines.
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is of its assets, above the one-third ceiling the screen allows.Fail
Interest-bearing cashInterest-bearing cash and securities are of assets, above the one-third limit.Fail
ReceivablesMoney owed to the company is of assets, above the 49% limit.Fail
Revenue purityOnly 0.0% of revenue comes from non-compliant sources — under the 5% line.Pass
Five checks adapted from AAOIFI screening standards — business activity plus four balance-sheet ratios. All five must pass for ethical clearance.
OPPORTUNITY
The opportunity · what the numbers say it is worth
Read at
$10.94
N/A P/E · 7.60 fwd
Our fair value
$21.88
100% discount
Analyst target (avg)
$25.50
+133% to current
Target low $13.00Analyst target rangeTarget high $29.00
▲ current $10.94 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$10.94
you are here
Conservative
$21.88
+100%
Analyst avg
$25.50
+133%
Our fair value
$21.88
+100%
Analyst high
$29.00
+165%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Revenue growth
104.40%
Profit margin
-76.77%
Analyst consensus
Strong Buy · 10 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
PLAIN
The business, in plain words · what the numbers mean
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
PEERS
Related securities · others in PHAT's space worth a look
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
PHAT trades on Nasdaq. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (10 analysts) rates it strong buy, with a mean price target of $24. Entered 2026-07-18 · Markdown
JOURNAL
The dated journal · newest first, never edited
2026-07-18Markdown$10.37+0.0%Entry 3
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (10 analysts) rates it strong buy, with a mean price target of $24.
2026-07-03Markdown$10.37+0.0%Entry 2
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markdown$10.37Entry 1
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
RETURNS
What holding actually paid · price plus dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$12.22
-18.5%
·
$815
-18.5%
2 months
$12.63
-21.2%
·
$788
-21.2%
3 months
$10.22
-2.6%
·
$974
-2.6%
6 months
$14.57
-31.7%
·
$683
-31.7%
1 year
$8.97
+11.0%
·
$1,110
+11.0%
2 years
$10.74
-7.3%
·
$927
-7.3%
3 years
$12.99
-23.4%
·
$766
-23.4%
5 years
$34.71
-71.3%
·
$287
-71.3%
Historical returns from market close data. Past performance does not guarantee future results.
SEALED
This entry now belongs to the ledger. Whatever PHAT does next, these words stay.
Phathom Pharmaceuticals, Inc. · PHAT · Markdown · $10.94
Recorded 2026-07-19 · before the outcome · scored mechanically